The AtlanticAn Astonishing Video Shows CRISPR Editing DNA in Real Time …The AtlanticI was sitting in the front, and I just heard this gasp from everyone behind me.”CRISPR Can Now Edit Genes Using Nanoparticles Instead of VirusesMotherboardCRISPR-carr… Continue reading
The ScientistResearchers Build a Cancer Immunotherapy Without Immune CellsThe Scientist“A slightly more significant issue is that the way the immune system is configured, immune cells are more likely to seek out a tumor than non-immune cells, so how us… Continue reading
The MIT TechCRISPR-carrying nanoparticles edit the genomeThe MIT TechIn a new study, MIT researchers have developed nanoparticles that can deliver the CRISPR genome-editing system and specifically modify genes in mice. The team used nanoparticles to ca… Continue reading
Princeton Alumni Weekly |
An Exploration of The Potential of Stem Cells
Princeton Alumni Weekly The book: Promising stem cell treatments are being tested in thousands of clinical trials throughout the United States. These treatments use adult stem cells found in people’s own bodies to help eliminate cancer, for organ replacement, and to use the … Two Day Seminar: FDA’s Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering …Business Wire (press release) Rutgers-Led Study: Inner Ear Stem Cells May Someday Restore Hearing, But Could Increase Cancer RiskTAPinto.net Stem Cell Banking market to 2022: consumption volume, value, import, export and sale price analysis available in new …Expert Herald MilTech –satPRnews (press release) –The Global Health News (press release) (blog) all 25 news articles » |
Prostate Cancer News Today |
P-PSMA-101 Generates Long-Lasting Response to Prostate Cancer, Mouse Study Shows
Prostate Cancer News Today P-PSMA-101 is a CAR T-cell therapy that targets the PSMA protein found at high levels in prostate cancer. The name CAR T-cell comes from the approach used to fight cancer — modifying a person’s own immune T-cells. Scientists said the treatment’s … |
Targeted Oncology |
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
Targeted Oncology Chimeric antigen receptor (CAR) T cells have hit the prime time, with 2 FDA approvals already for this class of cellbased therapy. Undoubtedly this will be a game changer for patients with B-cell malignancies who have a small number of treatment … Bluebird Bio’s CAR T-Cell Therapy Stopped Progression of Hard-to-Treat MyelomaMyeloma Research News |